Although rare in pediatric B-ALL cases treated with chemotherapy [42], lineage switch or myeloid feature acquisition occurs in up to 10% of patients treated with CD19-directed immunotherapy [13, 14]. This evidence concerns the gene CD19 and precursor B-cell acute lymphoblastic leukemia.